




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 307/80, 333/60, 215/12, 405/06, 409/06, A61K 31/47, 31/445, 31/34, 31/38		A1	(11) International Publication Number: WO 98/01436
(21) International Application Number: PCT/EP97/03709		(43) International Publication Date: 15 January 1998 (15.01.98)	
(22) International Filing Date: 7 July 1997 (07.07.97)		(74) Agent: RUTTER, Keith; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).	
(30) Priority Data: 9614347.4 9 July 1996 (09.07.96) GB		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(71) Applicants (for all designated States except US): SMITHKLINE BEECHAM S.P.A. [IT/IT]; Via Zambelletti, I-20021 Baranzate di Bollate (IT). SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES [FR/FR]; 6, esplanade Charles de Gaulle, F-92731 Nanterre Cedex (FR).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): FARINA, Carlo [IT/IT]; SmithKline Beecham S.p.A., Via Zambelletti, I-20021 Baranzate di Bollate (IT). GAGLIARDI, Stefania [IT/IT]; SmithKline Beecham S.p.A., Via Zambelletti, I-20021 Baranzate di Bollate (IT). NADLER, Guy, Marguerite, Marie, Gerard [FR/FR]; SmithKline Beecham Laboratoires Pharmaceutiques, Unité de Recherche, 4, rue de Chesnay-Beauregard, Boîte postale 58, F-35762 Saint-Grégoire Cedex (FR). MARTIN, Michel, Jean, Roger [FR/FR]; SmithKline Beecham Laboratoires Pharmaceutiques, Unité de Recherche, 4, rue de Chesnay-Beauregard, Boîte postale 58, F-35762 Saint-Grégoire Cedex (FR).			

(54) Title: **HETEROAROMATIC PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION**

(57) Abstract

A compound of formula (I) or a salt thereof, or a solvate thereof, wherein: R₁ represents an alkyl group or a substituted or unsubstituted aryl group; R₂, R₃ and R₄ each independently represent hydrogen, alkyl, aryl or substituted aryl; R₅ and R₆ each independently represent hydrogen, hydroxy, amino, alkoxy, optionally substituted aryloxy, optionally substituted benzyloxy, alkylamino, dialkylamino, halo, trifluoromethyl, trifluoromethoxy, nitro, alkyl, carboxy, carbalkoxy, carbamoyl, alkylcarbamoyl, or R₅ and R₆ together represent methylenedioxy, carbonyldioxy or carbonyldiamino; X represents a hydroxy or an alkoxy group wherein the alkyl group may be substituted or unsubstituted or X represents a group NR₇R₈ wherein R₇ and R₈ each independently represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, an optionally substituted heterocyclic group or an optionally substituted heterocyclylalkyl group, or R₇ and R₈ together with the nitrogen to which they are attached form a heterocyclic group; and Y represents O or S and Z represents CH, CH=CH or N; or Y represents NR₇ wherein R₇ represents hydrogen, hydroxy, alkanoyl, alkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, carbalkoxyalkyl, carbamoyl or aminosulphonyl and Z represents CH=CH or N; a pharmaceutical composition containing such a compound, a process for preparing such a compound and the use of such a compound in medicine.



a group NR₇R₈ wherein R₇ and R₈ each independently represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, an optionally substituted heterocyclic group or an optionally substituted heterocyclylalkyl group, or R₇ and R₈ together with the nitrogen to which they are attached form a heterocyclic group; and Y represents O or S and Z represents CH, CH=CH or N; or Y represents NR₇ wherein R₇ represents hydrogen, hydroxy, alkanoyl, alkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, carbalkoxyalkyl, carbamoyl or aminosulphonyl and Z represents CH=CH or N; a pharmaceutical composition containing such a compound, a process for preparing such a compound and the use of such a compound in medicine.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HETEROAROMATIC PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION

5 This invention relates to certain novel compounds, to a process for preparing such compounds, to pharmaceutical compositions containing such compounds and to the use of such compounds and compositions in medicine.

Co-pending International Application, application number PCT/EP96/00157 discloses certain indole derivatives which are indicated to reduce bone resorption by inhibiting osteoclast H^+ -ATPase.

10 Diseases associated with loss of bone mass are known to be caused by over activity of osteoclast cells. It is also known that certain compounds, usually related to bafilomycin, are useful for treating such diseases: For example International Patent Application, publication number WO 91/06296 discloses certain bafilomycin macrolides for the treatment of bone affecting diseases.


15 However, bafilomycin derivatives are not selective for osteoclasts in humans. The use of these compounds is therefore associated with unacceptable toxicity due to generalised blockade of other essential v-ATPases. Indeed, to date there is no known treatment which is selective for the human osteoclasts.

20 The search for a successful treatment for diseases associated with loss of bone mass in humans is further complicated in that the nature of the therapeutic target for the selective inhibition of the osteoclasts is controversial. Thus Baron *et al* (International Patent Application publication number WO93/01280) indicate that a specific vacuolar ATPase (V-ATPase) has been identified in osteoclasts as a potential therapeutic target. However, the Baron work was carried out in chickens and Hall *et al* (Bone and Mineral 27, 1994, 159-166), in a study relating to mammals, conclude that in contrast to avian
25 osteoclast V-ATPase, mammalian osteoclast V-ATPase is pharmacologically similar to the v-ATPase in other cells and, therefore, it is unlikely to be a good therapeutic target.

30 We have now found a group of compounds which are selective for mammalian osteoclasts, acting to selectively inhibit their bone resorbing activity. These compounds are therefore considered to be particularly useful for the treatment and/or prophylaxis of diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases. These compounds are also considered to possess anti-tumour activity, antiviral activity (for example against *Semliki Forest*, *Vesicular Stomatitis*, *Newcastle Disease*, *Influenza A and B*, *HIV* viruses), antiulcer activity (for example the compounds may be useful for the treatment of chronic

gastritis and peptic ulcer induced by *Helicobacter pylori*), immunosuppressant activity, antilipidemic activity, antiatherosclerotic activity and to be useful for the treatment of AIDS and Alzheimer's disease. In a further aspect, these compounds are also considered useful in inhibiting angiogenesis, i.e. the formation of new blood vessels which is observed in various types of pathological conditions (*angiogenic diseases*) such as rheumatoid arthritis, diabetic retinopathy, psoriasis and solid tumours.

Accordingly, the present invention provides a compound of formula (I):



(I)

or a salt thereof, or a solvate thereof, wherein:

R₁ represents an alkyl group or a substituted or unsubstituted aryl group;

R₂, R₃ and R₄ each independently represent hydrogen, alkyl, aryl or substituted aryl;

R₅ and R₆ each independently represents hydrogen, hydroxy, amino, alkoxy, optionally substituted aryloxy, optionally substituted benzyloxy, alkylamino, dialkylamino, halo, trifluoromethyl, trifluoromethoxy, nitro, alkyl, carboxy, carbalkoxy, carbamoyl, alkylcarbamoyl, or R₅ and R₆ together represent methylenedioxy, carbonyldioxy or carbonyldiamino;

X represents a hydroxy or an alkoxy group wherein the alkyl group may be substituted or unsubstituted or X represents a group NR_sR_t wherein R_s and R_t each independently represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, an optionally substituted heterocyclic group or an optionally substituted heterocyclalkyl group, or R_s and R_t together with the nitrogen to which they are attached form a heterocyclic group; and

Y represents O or S and Z represents CH, CH=CH or N; or

Y represents NR₇ wherein R₇ represents hydrogen, hydroxy, alkanoyl, alkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, carbalkoxyalkyl, carbamoyl or aminosulphonyl and Z represents CH=CH or N.

Suitably, Y represents O or S and Z represents CH, CH=CH or N, especially CH or CH=CH.

In one aspect R₁ represents alkyl, alkoxyalkyl or substituted or unsubstituted phenyl.

Suitably, R₁ represents a C₁₋₄-alkyl group, for example methyl or ethyl.

Preferably, R₁ represents methyl.

In one aspect, R₂, R₃ and R₄ each independently represent hydrogen, alkyl or phenyl.

An example of R₂ is hydrogen.

5 An example of R₃ is hydrogen.

An example of R₄ is hydrogen.

Suitably, R₅ and R₆ each independently represents hydrogen or a halo atom.

When R₅ or R₆ represents halo, said halo group is suitably a fluoro or chloro group.

10 An example of a halo is chloro.

Suitable positions for substitution for R₅ or R₆ are the 4, 5, 6 or 7 position, favourably the 5 or 6 position.

When X represents an alkoxy group, the alkyl group thereof is preferably an unsubstituted alkyl group.

15 An example of an alkoxy group represented by X is a methoxy group.

Suitably, X represents the above defined group N R_s R_t.

When R_s or R_t represent alkyl or substituted alkyl, suitable alkyl groups are C₁₋₆ alkyl groups, for example C₁, C₂, C₃, C₄ and C₅ alkyl groups, favourably ethyl, propyl or butyl.

20 When R_s or R_t represent substituted alkyl, favoured groups are 2-(dialkylamino)ethyl or 3-(dialkylamino)propyl or 4-(dialkylamino)butyl or heterocyclylmethyl or heterocycylethyl or heterocyclylpropyl groups, especially 3-(dialkylamino) propyl groups. An example of a 3-(dialkylamino) propyl group is a 3-(diethylamino) propyl group.


25 When R_s or R_t represent alkenyl or substituted alkenyl, suitable alkenyl groups are C₂₋₆ alkenyl groups, for example a C₅ alkenyl group.

When R_s or R_t represent aryl or substituted aryl, suitable aryl groups are phenyl groups.

In one aspect, R_s and R_t together represent a heterocyclic group.

30 In one favoured aspect R_t is hydrogen.

A particular 6 membered, saturated heterocyclic group is a group of formula (H1):



(H1)

wherein X_1 , X_2 , X_3 , X_4 , X_5 , X_6 , X_7 and X_8 are each independently selected from
 5 hydrogen, hydroxy, (C_1 - C_6), alkyl cycloalkyl (spirocondensed), mono or poly hydroxyalkyl, alkoxyalkyl, hydroxy-alkoxyalkyl, alkanoyl, alkoxy carbonyl, aminoalkyl (optionally alkylated or acylated at nitrogen);

or one of X_4 with X_6 and X_2 with X_8 represents a C_{2-4} alkylene chain and the remaining
 10 variables X_1 , X_3 , X_7 and X_7 each independently represent hydrogen, hydroxy, lower alkyl (C_1 - C_6), cycloalkyl (spirocondensed), mono or poly hydroxyalkyl, alkoxyalkyl, hydroxy-alkoxyalkyl, alkanoyl, alkoxy carbonyl, aminoalkyl (optionally alkylated or acylated at nitrogen); and X_5 represents hydrogen or lower alkyl, mono or polyhydroxyalkyl, mono or diaminoalkyl, aminocarbonyl, alkyl, carboxyalkyl, carbalkoxyalkyl, aryl, heterocyclyl, acyl, carbamoyl, alkylamino(cyanimidoyl), aminoalkanoyl, hydroxyalkanoyl.

15 Suitably, X_1 , X_2 , X_8 and X_9 each represent hydrogen.

Suitably, X_3 , and X_4 each independently represent hydrogen or alkyl, especially alkyl.

Suitably, X_6 and X_7 each independently represent hydrogen or alkyl.

Suitably, X_5 represents alkyl

20 In one preferred aspect X_3 , X_4 , X_6 and X_7 each independently represent alkyl, especially methyl and X_1 , X_2 , X_8 and X_9 each represent hydrogen.

Particular examples of the invention are the compounds of example numbers: 3, 5, 8, 9 and 12.

25 As used herein, the term "alkyl" includes straight or branched chain alkyl groups having from 1 to 12, suitably 1 to 6, preferably 1 to 4, carbon atoms, such as methyl, ethyl, n- and iso- propyl and n- iso-, tert-butyl and pentyl groups, and also includes such alkyl groups when forming part of other groups such as alkoxy or alkanoyl groups.

Suitable optional substituents for any alkyl group include hydroxy; alkoxy; a group of formula $NR_U R_V$ wherein R_U and R_V each independently represent hydrogen, optionally

substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, carboxy, carboxyalkyl, or alkoxy carbonyl, nitro, or R_U and R_V together together with the nitrogen to which they are attached form an optionally substituted
5 heterocyclic ring; carboxy; alkoxy carbonyl; alkoxy carbonylalkyl; alkylcarbonyloxy; alkylcarbonyl; mono- and di-alkylphosphonate; optionally substituted aryl; and optionally substituted heterocyclyl.

A preferred alkyl substituent is $NR_U R_V$, wherein R_U and R_V each independently represent hydrogen, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl or R_U and R_V together
10 together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring.

As used herein, the term "alkenyl" includes straight or branched chain alkenyl groups having from 2 to 12, suitably 2 to 6 carbon and also includes such groups when
15 forming part of other groups, an example is a butenyl group, such as a 2-butenyl group.

Suitable optional substituents for any alkenyl group includes the alkyl substituents mentioned above.

As used herein, the term "aryl" includes phenyl and naphthyl, especially phenyl.

Suitable optional substituents for any aryl group include up to 5 substituents, suitably up to 3 substituents, selected from alkyl, substituted alkyl, alkoxy, hydroxy, halogen, trifluoromethyl, acetyl, cyano, nitro, amino, mono- and di-alkylamino and
20 alkylcarbonylamino.

Preferred optional substituents for any aryl group are selected from isobutyl, hydroxy, methoxy, phenoxy, diethylaminoethoxy, pyrrolidinoethoxy, carboxymethoxy, pyridyloxy, fluoro, chloro, amino, dimethylamino, aminomethyl, morpholino,
25 bis(carbethoxy)hydroxymethyl,

Suitable arylalkyl groups include aryl- C_{1-3} -alkyl groups such as phenylethyl and benzyl groups, especially benzyl.

Preferably, substituted aralkyl groups are substituted in the aryl moiety.

30 As used herein, the terms "heterocyclyl" or "heterocyclic" include saturated or unsaturated single or fused, including spiro, ring heterocyclic groups, each ring having 4 to 11 ring atoms, especially 5 to 8, preferably 5, 6 or 7 which ring atoms include 1, 2 or 3 heteroatoms selected from O, S, or N.

Suitable heterocyclic groups include single ring saturated heterocyclic groups, single ring unsaturated heterocyclic groups, fused ring heterocyclic groups.

Fused ring heterocyclic groups include spiro heterocyclic groups.

5 Suitable single ring unsaturated heterocyclic groups comprise 5-, 6- or 7-membered rings.

10 Suitable 5-membered single ring unsaturated heterocyclic groups are furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, furazanyl, thiazolyl and isothiazolyl groups; or partially saturated derivatives thereof, such as 4,5-dihydro-1,3-thiazol-2-yl, 1H-imidazolinyl, pyrrolinyl, pyrazolinyl, oxazolinyl, isoxazolinyl, thiazolinyl groups.

15 Suitable 6-membered single ring unsaturated heterocyclic groups are pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, 1,2- or 1,3- or 1,4-oxazinyl, 1,2- or 1,3- or 1,4-thiazinyl and pyranyl groups, or partially saturated derivatives thereof such as 1,2- or 1,3- or 1,4- dihydrooxazinyl, 1,4-dihydropyridyl, dihydropyridazinyl, dihydropyrazinyl or dihydropyrimidinyl.

Suitable 7-membered single ring unsaturated heterocyclic groups are azepinyl, oxepinyl, diazepinyl, thiazepinyl, oxazepinyl or partially saturated derivatives thereof.

Suitable, single ring saturated heterocyclic groups comprise 5-, 6- or 7- membered rings.

20 Suitable 5-membered single ring saturated heterocyclic groups are pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl and tetrahydrofuranyl groups.

Suitable 6-membered single ring saturated heterocyclic groups are piperidinyl, piperazinyl, tetrahydropyranyl, 1,3-dioxacyclohexyl, tetrahydro-1,4-thiazinyl, morpholinyl and morpholino groups.

25 Suitable 7-membered single ring saturated heterocyclic groups are hexamethyleniminyl, oxepanyl and thiepanyl.

Suitable fused ring heterocyclic groups include fused saturated rings, fused unsaturated rings and saturated rings fused to unsaturated rings.

30 Suitable groups having fused saturated rings are quinuclidyl, 8-azabicyclo[3.2.1]octyl, 9-azabicyclo[3.3.1]nonyl, 1-azabicyclo[3.3.3]undecyl, 1,9-diazabicyclo[3.3.1]nonyl and 1,5-diazabicyclo[3.3.1]nonyl groups.

Suitable groups having fused unsaturated rings are pyrazo[3.4-d]pyrimidinyl, 1,2,5-thiadiazolo[3,4-b]pyridyl, isoxazolo[4,5-b]pyridyl, thiazolo[4,5-b]pyridyl,

oxazolo[4,5-d]pyrimidinyl, 7H-purin-2-yl, quinolyl, isoquinolyl, benzo[b]thienyl, benzofuranyl, isobenzofuranyl, benzoxazolyl, benzothiazolyl, indoliziny, indolyl, isoindolyl, indazolyl, phthalazinyl, naphthyridinyl, quinoxaliny, quinazoliny, cinnoliny, pteridinyl and β -carboliny groups.

- 5 Suitable groups having saturated rings fused to unsaturated rings includes groups which are fused to benzene rings such as tetrahydroquinolyl, 4H-quinoliziny, tetrahydroisoquinolyl, dihydrobenzofuryl, chromenyl, chromanyl, isochromanyl, indoliny and isoindoliny groups.

- Suitable spiro heterocyclic groups include oxaspiro[4.5]decyl,
10 azaspiro[4.5]decyl, 1,2,4- triazaspiro[5.5]undecyl, 1,4-dioxo-9-azaspiro[4.7]dodecyl and 1-azaspiro[5.5]undecyl

- Suitable optional substituents for any heterocyclyl or heterocyclic group include up to 5 substituents, suitably up to 3 substituents, selected from alkyl, substituted alkyl, alkoxy, hydroxy, halo, amino, mono- or di-alkyl amino, alkoxycarbonyl, hydroxyalkyl,
15 alkoxyalkyl, hydroxyalkoxyalkyl, alkoxyalkoxyalkyl, aryl, aryloxy and heterocyclyl.

 Preferred optional substituents for any heterocyclyl or heterocyclic group are selected from isobutyl, hydroxy, methoxy, phenoxy, diethylaminoethoxy, pyrrolidinoethoxy, carboxymethoxy, pyridyloxy, fluoro, chloro, amino, dimethylamino, aminomethyl, morpholino, bis(carbethoxy)hydroxymethyl.

- 20 For the avoidance of doubt a reference herein to "heterocyclic" includes a reference to "heterocyclyl".

 As used herein, the term "halo" includes fluoro, chloro and bromo, suitably fluoro and chloro, favourably chloro.

- Certain of the carbon atoms of the compounds of formula (I) - such as those
25 compounds wherein R₁-R₄ contains chiral alkyl chains are chiral carbon atoms and may therefore provide stereoisomers of the compound of formula (I). The invention extends to all stereoisomeric forms of the compounds of formula (I) including enantiomers and mixtures thereof, including racemates. The different stereoisomeric forms may be separated or resolved one from the other by conventional methods or any given isomer
30 may be obtained by conventional stereospecific or asymmetric syntheses.

 The compounds of formula (I) also possess two double bonds and hence can exist in one or more geometric isomers. The invention extends to all such isomeric forms of the compounds of formula (I) including mixtures thereof. The different isomeric forms may be separated one from the other by conventional methods or any given isomer may be

obtained by conventional synthetic methods. Suitable salts of the compounds of the formula (I) are pharmaceutically acceptable salts.


Suitable pharmaceutically acceptable salts include acid addition salts and salts of carboxy groups.

- 5 Suitable pharmaceutically acceptable acid addition salts include salts with inorganic acids such, for example, as hydrochloric acid, hydrobromic acid, orthophosphoric acid or sulphuric acid, or with organic acids such, for example as methanesulphonic acid, toluenesulphonic acid, acetic acid, propionic acid, lactic acid, citric acid, fumaric acid, malic acid, succinic acid, salicylic acid, maleic acid or acetylsalicylic acid.
- 10 Suitable pharmaceutically acceptable salts of carboxy groups include metal salts, such as for example aluminium, alkali metal salts such as sodium or potassium and lithium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with C₁₋₆ alkylamines such as triethylamine, hydroxy-C₁₋₆ alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or
- 15 tri-(2-hydroxyethyl)-amine, cycloalkylamines such as dicyclohexylamine, or with procaine, 1,4-dibenzylpiperidine, N-benzyl-β-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine or quinoline.


- 20 Suitable solvates of the compounds of the formula (I) are pharmaceutically acceptable solvates, such as hydrates.


- 25 The salts and/or solvates of the compounds of the formula (I) which are not pharmaceutically acceptable may be useful as intermediates in the preparation of pharmaceutically acceptable salts and/or solvates of compounds of formula (I) or the compounds of the formula (I) themselves, and as such form another aspect of the present invention.

A compound of formula (I) or a salt thereof or a solvate thereof, may be prepared by reacting a compound of formula (II):



wherein R_2 , R_3 , R_4 , R_5 , R_6 , Y and Z are as defined in relation to formula (I), with a


reagent capable of converting a moiety of formula  into a moiety of formula (a);



- 5 wherein R_1 , R_2 , R_3 , R_4 and X are as defined in relation to formula (I);
and thereafter, as necessary, carrying out one or more of the following reactions:
- (i) converting one compound of formula (I) into another compound of formula (I);
 - (ii) removing any protecting group;
 - (iii) preparing a salt or a solvate of the compound so formed.


10

A suitable reagent capable of converting a moiety of the above defined formula




into a moiety of the above defined formula (a), includes conventional reagents used to convert $C=O$ bonds into carbon carbon double bonds, such as Wittig or Horner-Emmons reagents, for example a compound of formula (III):


15



wherein R_1 is as defined in relation to the compounds of formula (I), X_9 represents X as defined in relation to formula (I) or a group convertible thereto and X_{10} represents a moiety $(R_8O)_2P(O)-$ wherein R_8 is C_{1-4} alkyl, especially ethyl, or X_{10} is a group Ph_3P- .

- 20 The reaction between the compounds of formula (II) and the reagent capable of



converting the group of formula  into the moiety of formula (a), may be

carried out under the appropriate conventional conditions, depending upon the particular reagent chosen, for example:

When the reagent is a compound of formula (III) wherein X_{10} is a moiety $(R_8O)_2P(O)-$, then the reaction is carried out under conventional Horner-Emmons conditions, using any suitable, aprotic solvent for example an aromatic hydrocarbon such as benzene, toluene or xylene, DMF, DMSO, chloroform, preferably, dichloromethane, dioxane, THF, acetonitrile, N-methylpyrrolidone, and the like or mixtures thereof, preferably an anhydrous solvent, at a temperature providing a suitable rate of formation of the required product, conveniently at ambient temperature or at an elevated temperature, such as a temperature in the range of from 30°C to 120°C, for examples 90°C; preferably the reaction is conducted in the presence of a base.


Suitable bases for use in the last above mentioned reaction include organic bases, such as butyl lithium, lithium diisopropylamide (LDA), N,N-diisopropylethylamine, 1,5-diazabicyclo[4.3.0]-5-nonene (DBN), preferably, 1,5-diazabicyclo[5.4.0]-5-undecene (DBU), 1,5-diazabicyclo[2.2.2]octane (DABCO), and inorganic bases, such as sodium hydride; and generally the reaction is carried out in an inert atmosphere such as nitrogen.

When the reagent is a compound of formula (III) wherein X_{10} is a moiety Ph_3P- , then the reaction is carried out under conventional Wittig conditions. Usually, the reaction is carried out in the presence of a base, in any suitable aprotic solvent. Suitable bases are organic bases such as triethylamine, trimethylamine, N,N-diisopropylethylamine (DIPEA), pyridine, N,N-dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo[4.3.0]-5-nonene (DBN), 1,5-diazabicyclo[5.4.0]-5-undecene (DBU), 1,5-diazabicyclo[2.2.2]octane (DABCO) and inorganic bases such as sodium hydride, caesium carbonate, potassium carbonate, preferably sodium hydride. Suitable solvents are conventional solvents for use in this type of reaction, such as aromatic hydrocarbons such as benzene, toluene or xylene or the like: DMF, DMSO, chloroform, dioxane, dichloromethane, THF, ethyl acetate, acetonitrile, N-methylpyrrolidone or mixtures thereof, preferably dichloromethane. This reaction is carried out at any temperature providing a suitable rate of formation of the required product, conveniently at ambient temperature or at an elevated temperature, such as a temperature in the range of from -20°C to 140°C, preferably in the range of from about room temperature to the reflux temperature of the solvent.

Suitably, in the compound of formula (III), X_9 represents X when a hydroxy or alkoxy group in which the alkyl group may be substituted or unsubstituted; the compound of formula (I) prepared therefrom is then suitably converted to further compounds of formula (I) using methods described below.


A compound of formula (II) may be prepared according to the reaction sequences shown in Schemes (Ia-c) below

Scheme (Ia)




5

Scheme (Ib)



Scheme (Ic)



10

wherein, subject to any qualification mentioned below R_2 , R_3 , R_4 , R_5 , R_6 , X, Y and Z are as defined in relation to the compounds of formula (I).

Compounds of formula (II) may be prepared by the Wittig reaction of keto derivatives of formula (IV) with an appropriate phosphonium salt or by reaction of keto derivative (IV) with an appropriate Horner Emmons reagent. Respective reaction conditions are the appropriate conventional conditions, for example for the Wittig reaction those described in "The Wittig Reaction", R. Adams Ed., Vol. 14, p. 270 (1965) or in *Angew. Chem. Int. Ed. Engl.*, **4**, 645 (1965) and for the Horner Emmons reaction those reported, in *Tetrahedron Lett.* **1981**, 461; *Can. J. Chem.*, **55**, 562 (1997); *J. Am. Chem. Soc.*, **102**, 1390 (1980); *J. Org. Chem.*, **44**, 719 (1979); *Syntheses*, **1982**, 391; and *Tetrahedron Lett.* **1982**, 2183.

When R_2 is other than -H, e.g. alkyl, a compound of formula (II) is obtained directly from a compound of formula (IV) by Wittig or Horner-Emmons reaction with the appropriate phosphonium salts or phosphonates according to Scheme (Ia).

The reaction of compounds of formula (IV) with the above mentioned phosphonium salts are carried out in the presence of a base in any suitable solvent. Suitable bases include organic bases, such as triethylamine, trimethylamine, N,N-diisopropylethylamine (DIPEA), pyridine, N,N-dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo[4.3.0]-5-nonene (DBN), 1,5-diazabicyclo[5.4.0]-5-undecene (DBU), 1,5-diazabicyclo[2.2.2]octane (DABCO) and inorganic bases, such as sodium hydride, caesium carbonate, potassium carbonate. Suitable solvents include conventionally used solvents, for example aromatic hydrocarbons such as benzene, toluene or xylene or the like; DMF, DMSO, chloroform, dioxane, dichloromethane, THF, ethyl acetate, acetonitrile, N-methylpyrrolidone and the like or mixtures thereof. Preferably, the reaction is carried out at a reaction temperature of in the range of about -20°C to 140°C, preferably about room temperature to the reflux temperature of the solvent.


The reaction of compounds of formula (IV) with phosphonates are carried out under conventional Horner-Emmons conditions, using any suitable, aprotic solvent for example an aromatic hydrocarbon such as benzene, toluene or xylene, DMF, DMSO, chloroform, dioxane, dichloromethane, preferably, THF, acetonitrile, N-methylpyrrolidone, and the like or mixtures thereof, preferably an anhydrous solvent, at a temperature providing a suitable rate of formation of the required product, conveniently at ambient temperature or at an elevated temperature, such as a temperature in the range of from 30°C to 120°C; preferably the reaction is conducted in the presence of a base. Suitable bases for use in this reaction include organic bases, such as butyl lithium, lithium

diisopropylamide (LDA), N,N-diisopropylethylamine, 1,5-diazabicyclo[4.3.0]-5-nonene (DBN), 1,5-diazabicyclo[5.4.0]-5-undecene (DBU), 1,5-diazabicyclo[2.2.2]octane (DABCO), and inorganic bases, such as sodium hydride; preferably sodium hydride, and generally the reaction is carried out in an inert atmosphere such as nitrogen.

5 For compounds of formula (I) wherein R_2 and $R_4 = H$, an aldehyde of formula (V) is reacted with an aliphatic aldehyde of formula (VI) (Scheme (Ib)), in presence of an inorganic base such as sodium or potassium hydroxide affording compound (II) using the appropriate conventional procedure.

Alternatively, compounds of formula (I) wherein R_2 and $R_4 = H$ may be prepared as shown in Scheme (Ic) in which a compound of formula (IV) is reacted with a substituted carbethoxymethylphosphonium salt or carbethoxymethylphosphonate, the resulting carboxylic ester (VII) is then converted into the corresponding alcohol by reduction agent, suitably using a complex metal reducing agent such as lithium aluminium hydride ($LiAlH_4$), diisobutyl aluminium hydride (DIBAL) or lithium borohydride ($LiBH_4$), in any suitable aprotic solvent for example methylene dichloride, chloroform, dioxane, diethyl ether or THF, at any temperature providing a suitable rate of formation of the required product, such as a temperature in the range of from $-30^\circ C$ to $60^\circ C$, for example at room temperature. The intermediate alcohol is then oxidised to aldehyde (II) with an oxidising agent such as manganese dioxide, periodinane (Dess-Martin reagent), pyridinium chlorochromate (PCC) or pyridinium dichromate (PDC) or a combination of oxalyl chloride and DMSO (Swern reaction), preferably manganese dioxide in methylene dichloride.

The compounds of formula (III) can be prepared according to the reaction sequence shown in Scheme (II) below:



wherein, subject to any qualification mentioned below, R₁ and R₈ are as defined in relation to formula (I) and X₉ is as defined in relation to formula (III).

The starting material is an α -alkoxycarboxylic ester of formula (VIII) which is commercially available or which is prepared according to the methods known in the art, for example those reported in *Rodd's Chemistry of Organic Compounds, Vol ID, p. 96 (1965)*, S. Coffey Ed., Elseviers. The compound of formula (VIII) is reacted with an N-haloimide, for example N-bromosuccinimide in the presence of a radical producing agent such as azobisisobutyronitrile or benzoyl peroxide in a suitable solvent such as carbon tetrachloride, benzene, for example carbon tetrachloride and at a reaction temperature in the range of from

-30°C and 80°C, for example at room temperature; examples of such a reaction may be found in the literature, for example *J. Org. Chem.*, **41**, 2846 (1976). The halocompound obtained, of formula (IX), is then reacted either with triphenylphosphine or with a trialkyl phosphite $P(OR)_3$ to give the required compound of formula (III) as shown in Scheme (II).


When the compound of formula (IX) is reacted with triphenylphosphine, the reaction is performed in any conventionally used solvent, for example dioxane, tetrahydrofuran, benzene, xylene or, preferably, toluene at a suitable reaction temperature in the range of from -30°C to 80°C, for example at room temperature (examples of this conversion are reported in the literature, for example in *Chem. Ber.*, **97**, 1713 (1964)).

When the compound of formula (IX) is reacted with trialkyl phosphite $P(OR)_3$, the reaction is performed in any conventionally used solvent, preferably the trialkyl phosphite, and at a suitable reaction temperature, preferably at the boiling point of the solvent (examples of this conversion are reported in the literature, for example in *Liebigs Ann. Chem.*, **699**, 53 (1966)).

Alternatively, a compound of formula (III) in which R_2 is $(R_8O)_2PO$ may be prepared using the procedure depicted in Scheme (II), by reacting a diazophosphonoacetates of formula (X) with an alcohol or phenol of formula R_1OH , wherein R_1 is as defined in relation to formula (I), in the presence of rhodium^{II} acetate as described in the literature, for example in *Tetrahedron*, **50**, 3177 (1994) or in *Tetrahedron*, **48**, 3991 (1992).

The compounds of formula (IV) wherein R_4 is other than hydrogen are known compounds or they are prepared using methods analogous to those used to prepare known compounds, such as those described in *J. Org. Chem.*, **47**, 757 (1982); *Heterocycles*, **22**, 1211 (1984); *Tetrahedron*, **44**, 443 (1988).


Also, the compounds of formula (IV) wherein R_4 is other than hydrogen can be prepared from aldehydes of formula (V) according to the following scheme:



- Reaction of compound (V) with 1,3-propanedithiol to give compound (XII) is carried out in the presence on a catalytic amount of acid, suitably p-toluenesulphonic acid, in toluene at the refluxing temperature in a Dean-Stark apparatus and removing azeotropically the water formed. Alkylation of compound (XII) with $R_4\text{Hal}$, in which Hal is an halogen, suitably bromo or iodo, is carried out in the presence of a base such as butyl lithium in anhydrous THF under an inert atmosphere at a temperature of between -30°C to room temperature (see, for example: *Tetrahedron*, **44**, 443-450, 1988). Conversion of compound (XIII) to compound (IV) can be performed with mercury salts.

- The compounds of formula (V) wherein Y is O and Z is CH, or wherein Y is N and Z is CH=CH, are commercially available compounds.

The compounds of formula (V) wherein Y is O, S or NH and Z is N or CH can be prepared by reaction of paraldehyde with a of compound formula (XI):



wherein R_5 is R_5 as defined in relation to formula (I) or a protected form thereof and R_6 is R_6 as defined in relation to formula (I) or a protected form thereof and X and Z are as defined in relation to formula (I).


5 The reaction between the compound of formula (XI) and paraldehyde is conveniently carried out in an aprotic solvent such as acetonitrile in the presence of hydrogen peroxide/ferrous sulphate, usually at an elevated temperature such as the reflux temperature of the solvent.

10 The compounds of formula (VI) and (VIII) are known compounds or they are prepared using methods analogous to those used to prepare known compounds, such as those described in J. March, *Advanced Organic Chemistry*, 3rd Edition (1985), Wiley Interscience.

15 The compounds of formula (XI) are known compounds or they are prepared using methods analogous to those used to prepare known compounds, such as those described in "*Rodd's Chemistry of carbon compounds*", Second Edition, S. Coffey and M.F. Ansell Ed., Vol. IV, Part C, Elseviers, 1986 and Supplement to the Second Edition, M.F. Ansell Ed., Vol. IV, Part C, Elseviers, 1994

20 Suitable conversions of one compound of formula (I) into another compound of formula (I) includes converting a compound of formula (I) wherein X represents a hydroxy group or an alkoxy group into a compound of formula (I) wherein X represents a different alkoxy group or a moiety of the above defined formula NR_5R_6 . Such conversions are shown below in Scheme (III):

Scheme (III)



- wherein, subject to any qualification mentioned below, $R_2, R_3, R_4, R_5, R_6, R_7, R_8, X, Y$ and Z are as defined in relation to the compounds of formula (I), R_5' is R_5 or a protected form thereof, R_t' is R_t or a protected form thereof and R' is X when X is an alkoxy group.

- The conversion of one compound of formula (I) into another compound of formula (I) may be carried out using the appropriate conventional procedure; for example, the above mentioned conversion of a compound wherein X represents a hydroxy group or an alkoxy group into a compound wherein X represents a moiety of the above defined formula NR_5R_t or another alkoxy group may be carried out as follows:

- (i) when X is alkoxy, by basic hydrolysis, using for example potassium hydroxide, to provide a compound of formula (I) wherein X is hydroxy, and thereafter (a) for preparing compounds wherein X represents a moiety of the above defined formula NR_5R_t , treating with a compound of formula $\text{HNR}_5'\text{R}_t'$ wherein R_5' and R_t' are as defined above or (b) for preparing compounds of formula (I) wherein X represents alkoxy, by treating with a compound of formula $\text{R}'\text{OH}$ wherein R' is the required alkoxy group; and thereafter optionally deprotecting; or
- (ii) when X is hydroxy, by using analogous procedures to those mentioned above in (i).

- Preferably the reaction with the compounds of formula $\text{HNR}_5'\text{R}_t'$ or with compounds of formula $\text{R}'\text{OH}$ takes place after activation of the carboxylic group.

A carboxyl group may be activated in conventional manner, for example, by conversion into an acid anhydride, acid halide, acid azide or an activated ester such as cyanomethyl ester, thiophenyl ester, p-nitrophenyl ester, p-nityrothiophenyl ester, 2,4,6-trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, N-
5 hydroxyphthalimido ester, 8-hydroxypiperidine ester, N-hydroxysuccinimide ester, N-hydroxybenzotriazole ester, or the carboxyl group may be activated using a carbodiimide such as N,N'-dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (WSC), either in the presence or the absence of
10 hydroxybenzotriazole (HOBt) or 1-hydroxy-7-azabenzotriazole (HOAt); or it may be activated using N,N'- carbonyldiimidazole, Woodward-K reagent, Castro's reagent or an isoxazolium salt.

Condensation of an activated carboxyl group with an amino group or with an alcoholic group may be carried out in the presence of a base, in any suitable solvent.: Suitable bases include organic bases, such as triethylamine, trimethylamine, N,N-
15 diisopropylethylamine (DIPEA), pyridine, N,N-dimethylaniline, 4-dimethylaminopyridine (DMAP), N-methylmorpholine, 1,5-diazabicyclo[4.3.0]-5-nonene (DBN), 1,5-diazabicyclo[5.4.0]-5-undecene (DBU), 1,5-diazabicyclo[2.2.2]octane (DABCO), and inorganic bases, such as potassium carbonate. Suitable solvents include conventionally used solvents, for example DMF, dimethyl sulfoxide (DMSO), pyridine, chloroform,
20 dioxane, dichloromethane, THF, ethyl acetate, acetonitrile, N-methylpyrrolidone and hexamethylphosphoric triamide and mixtures thereof. The reaction temperature may be within the usual temperature range employed in this type of condensation reaction, and generally in the range of about -40°C to about 60°C, preferably from about -20°C to about 40°C.

25 When the reaction is carried out in the presence of a suitable condensing agent, for example a carbodiimide, N,N'- carbonyldiimidazole, Woodward-K reagent, Castro's reagent or the like, the condensing agent is preferably employed in an amount from equimolar to about 5 times the molar quantity of the starting material and the reaction is performed in a suitable solvent for example a halogenated hydrocarbon such as
30 dichloromethane, chloroform, carbon tetrachloride, tetrachloroethane or the like; an ether such as dioxane, THF, dimethoxyethane or the like, a ketone such as acetone, methyl ethyl ketone or the like; acetonitrile, ethyl acetate, DMF, dimethylacetamide, DMSO or the like.. Preferably the condensation is carried out in an anhydrous solvent, and at a reaction temperature in the range of from about -10°C to 60°C, preferably about 0°C to room
35 temperature.


Alternatively, conversion of one compound of formula (I) in which X is O-alkyl into another compound of formula (I) in which X is $\text{NR}_\text{S}\text{R}_\text{t}$ may be effected by treating the said compound of formula (I) directly with a compound of formula $\text{HNR}_\text{S}\text{R}_\text{t}$ in the presence of a trialkylaluminium reagent such as trimethylaluminium or triethylaluminium, according to known procedures, such as those disclosed in *Tetrahedron Lett.*, **48**, 4171 (1977); and, if necessary, deprotecting or converting the compound of formula (I) in which X is $\text{NR}_\text{S}\text{R}_\text{t}$ into a compound of formula (I) in which X is $\text{NR}_\text{S}\text{R}_\text{t}$.


The trialkylaluminium reagent is generally employed in the above mentioned reactions in an amount of from equimolar to about 5 times the molar quantity of the starting material, preferably 2-3 times the molar quantity of the starting material and the reaction is performed in a suitable solvent for example a halogenated hydrocarbon such as dichloromethane, chloroform, carbon tetrachloride, tetrachloroethane or the like; an ether such as dioxane, THF, dimethoxyethane or the like. Preferably the condensation is carried out in an anhydrous solvent, and at a reaction temperature of about, generally -20°C to 120°C , preferably about 0°C to the reflux temperature of the solvent.

Amines of general formula $\text{HNR}_\text{S}\text{R}_\text{t}$ may be prepared using the methods known in the art for the preparation of amines, for example as taught in *Houben-Weil, Methoden der Organischen Chemie*, Vol. XI/1 (1957) and Vol. E16d/2 (1992), Georg Thieme Verlag, Stuttgart.

In particular, amines of the general formula $\text{HNR}_\text{S}\text{R}_\text{t}$ wherein one of R_S and R_t represents hydrogen and the other represents a moiety (a), (b), (c), (d) (e) as defined above or a particular example thereof, are prepared according to the methods summarised in Scheme (IV) below:

Scheme (IV)





wherein R is an alkyl or aryl group, R_{11} and R_V are as defined above, X_1 to X_9 are as defined for (H2), A is a bond or an alkyl chain, R_{10} is hydrogen (in ii) or halogen (in (iii)) and R_{11} is an alkyl group, R_{12} is alkyl or aryl, L and L_1 are leaving groups, for example halogen or mesylate, Y is halogen, Y_1 is a leaving group, for example a halogen and and Y_1 and Y_2 are leaving groups such as halogens, for example Y_1 is chloride and Y_2 is bromine.

With regard to Scheme (IV):

The reduction of the amide function in (i) is suitably carried out using known methods, for example by using mixed hydride reducing agents, such as lithium aluminium hydride and methods described in *Org Synth Coll Vol 4* 564.

The reduction of the nitropyridine in (ii) is suitably carried out using the method described in *J. Org. Chem.* **58**, 4742 (1993).

The alkylation of the hydroxy-nitropyridine in (ii) may be effected by using the method described in *J. Org. Chem* **55**, 2964 (1990).

The displacement reaction in (iii) is suitably carried out using the method described in *Helvetica Chimica Acta* **47** (2), 45 (1964)

The reduction of the nitrile in (v) is suitably carried by catalytic hydrogenation over platinum oxide.

- 5 The reaction of acid halide NC-A-COY to provide the dialkylphosphonate in (iv) is effected by following the procedure described in *J Org Chem* **36**, 3843 (1971).

The reaction of the azide with triphenylphosphine in (v) is carried out in wet tetrahydrofuran as described in *Bull Soc Chim Fr* **1985**, 815.

- 10 The azides in (v) are prepared as shown using azidotrimethylsilane, following the procedure described in *Synthesis* **1995**, 376.

The reaction of compound Y₁-A-Y₂ and the amine derivative in (v) proceeds under conventional displacement reaction conditions.

- 15 The reactions in (vi) can be performed using known, conventional methods, as described in J. March, *Advanced Organic Chemistry*, 3rd Edition, **1985**, Wiley Interscience. For example, oxidation can be performed using oxidising agents such as chromic acid (Jones reagent); reductive amination of the ketone in can be performed with benzylamine to give an imine intermediate which is then reduced using known methods and reducing agents such as sodium borohydride or lithium aluminium hydride. Debenzylation can then be performed again using conventional methods, for example with
- 20 hydrogen in the presence of a catalyst such as palladium on charcoal. Protection of ketone as the ethylene ketal can be performed with ethylene glycol under acidic catalysis; acylations or alkylations can be performed by treating the suitable piperidine derivatives with acyl or alkyl halides in the presence of an inorganic or organic base; deprotection of the dioxolane to the ketone can be effected by acidic treatment in aqueous or alcoholic
- 25 solvents. Protection on the primary amino group in 4 aminopiperidines can entail the use of classical carbamate protecting agents such as t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) or fluorenylmethoxycarbonyl (Fmoc), or of the phthalimido protecting group; the synthesis and the removal of such protective groups is described in, for example, in *Protective Groups in Organic Synthesis*, T. W Greene Ed., Wiley, New
- 30 York, **1981**. 4-Oxopiperidines can be converted into the corresponding oximes by treatment with hydroxyl- or alkoxyamine in a suitable solvent; reduction of the oxime to amine can be performed using conventional reducing agents such as lithium aluminium hydride or sodium cyanoborohydride.

The starting materials in the above reactions (i), (ii), (iii), (iv), (v) and (vi) are known commercially available compounds.

A compound of formula (I) or a solvate thereof may be isolated from the above mentioned processes according to standard chemical procedures.

- 5 The preparation of salts and/or solvates of the compounds of formula (I) may be performed using the appropriate conventional procedure.

If required mixtures of isomers of the compounds of the invention may be separated into individual stereoisomers and diastereoisomers by conventional means, for example by the use of an optically active acid as a resolving

- 10 agent. Suitable optically active acids which may be used as resolving agents are described in "*Topics in Stereochemistry*", Vol. 6, Wiley Interscience, 1971, Allinger, N.L. and Eliel, W.L. Eds.

Alternatively, any enantiomer of a compound of the invention may be obtained by stereospecific synthesis using optically pure starting materials of known configuration.

- 15 The absolute configuration of compounds may be determined by conventional methods such as X-ray crystallographic techniques.

The protection of any reactive group or atom, may be carried out at any appropriate stage in the aforementioned processes. Suitable protecting groups include those used conventionally in the art for the particular group or atom being protected.

- 20 Protecting groups may be prepared and removed using the appropriate conventional procedure, for example OH groups, including diols, may be protected as the silylated derivatives by treatment with an appropriate silylating agent such as di-*tert*-butylsilylbis(trifluoromethanesulfonate); the silyl group may then be removed using conventional procedures such as treatment with hydrogen fluoride, preferably in the form of a pyridine complex and optionally in the presence of alumina, or by treatment with
25 acetyl chloride in methanol. Alternatively benzyloxy groups may be used to protect phenolic groups, the benzyloxy group may be removed using catalytic hydrogenolysis using such catalysts as palladium (II) chloride or 10% palladium on carbon.

- 30 Amino groups may be protected using any conventional protecting group, for example *tert*-butyl esters of carbamic acid may be formed by treating the amino group with di-*tert*-butyldicarbonate, the amino group being regenerated by hydrolysing the ester under acidic conditions, using for example hydrogen chloride in ethyl acetate or trifluoroacetic acid in methylene dichloride. An amino group may be protected as a benzyl derivative, prepared from the appropriate amine and a benzyl halide under basic conditions, the benzyl

group being removed by catalytic hydrogenolysis, using for example a palladium on carbon catalyst.

Indole NH groups and the like may be protected using any conventional group, for example benzenesulphonyl, methylsulphonyl, tosyl, formyl, acetyl (all of them removable by treatment with alkaline reagents), benzyl (removable either with sodium in liquid ammonia or with AlCl_3 in toluene), allyl (removable by treatment with rhodium (III) chloride under acidic conditions), benzyloxycarbonyl (removable either by catalytic hydrogenation or by alkaline treatment), trifluoroacetyl (removable by either alkaline or acidic treatment), t-butyldimethylsilyl (removable by treatment with tetrabutylammonium fluoride), 2-(trimethylsilyl)ethoxymethyl (SEM) (removable by treatment with tetrabutylammonium fluoride in the presence of ethylenediamine), methoxymethyl (MOM) or methoxyethyl (MEM) groups (removed by mild acidic treatment).

Carboxyl groups may be protected as alkyl esters, for example methyl esters, which esters may be prepared and removed using conventional procedures, one convenient method for converting carbomethoxy to carboxyl is to use aqueous lithium hydroxide.

A leaving group or atom is any group or atom that will, under the reaction conditions, cleave from the starting material, thus promoting reaction at a specified site. Suitable examples of such groups unless otherwise specified are halogen atoms, mesyloxy, p-nitrobenzenesulphonyloxy and tosyloxy groups.

The salts, esters, amides and solvates of the compounds mentioned herein may as required be produced by methods conventional in the art: for example, acid addition salts may be prepared by treating a compound of formula (I) with the appropriate acid.

Esters of carboxylic acids may be prepared by conventional esterification procedures, for example alkyl esters may be prepared by treating the required carboxylic acid with the appropriate alkanol, generally under acidic conditions.

Amides may be prepared using conventional amidation procedures, for example amides of formula $\text{CONR}_\text{S}\text{R}_\text{I}$ may be prepared by treating the relevant carboxylic acid with an amine of formula $\text{HN R}_\text{S}\text{R}_\text{I}$ wherein R_S and R_I are as defined above. Alternatively, a C_{1-6} alkyl ester such as a methyl ester of the acid may be treated with an amine of the above defined formula $\text{HNR}_\text{S}\text{R}_\text{I}$ to provide the required amide.

As mentioned above the compounds of the invention are indicated as having useful therapeutic properties:

The present invention therefore provides a method for the treatment and/or prophylaxis of diseases associated with over activity of osteoclasts in mammals which

method comprises the administration of an effective non-toxic amount of a selective inhibitor of mammalian osteoclasts.

A suitable selective inhibitor of a mammalian osteoclast is a selective inhibitor of the vacuolar ATPase located on the ruffled border of mammalian osteoclasts.

- 5 One particular selective inhibitor of mammalian vacuolar ATPase is a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

- 10 Thus, the present invention further provides a method for the treatment of osteoporosis and related osteopenic diseases in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I) or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.

- 15 In a further aspect, the present invention provides an inhibitor of a mammalian osteoclasts, for example a compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.

- 20 In particular the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of osteoporosis and related osteopenic diseases.

Of particular interest is the osteoporosis associated with the peri and post menopausal conditions. Also encompassed are the treatment and prophylaxis of Paget's disease, hypercalcemia associated with bone neoplasms and all the types of osteoporotic diseases as classified below according to their etiology:

25 **Primary osteoporosis**

 Involutional

 Type I or postmenopausal
 Type II or senile

 Juvenile

- 30 **Idiopathic in young adults**

Secondary osteoporosis

 Endocrine abnormality

 Hyperthyroidism
 Hypogonadism

Ovarian agenesis or Turner's syndrome
Hyperadrenocorticism or Cushing's syndrome
Hyperparathyroidism

Bone marrow abnormalities

- 5 Multiple myeloma and related disorders
Systemic mastocytosis
Disseminated carcinoma
Gaucher's disease

Connective tissue abnormalities

- 10 Osteogenesis imperfecta
Homocystinuria
Ehlers-Danlos syndrome
Marfan's syndrome
Menke's syndrome

15 Miscellaneous causes

- Immobilisation or weightlessness
Sudeck's atrophy
Chronic obstructive pulmonary disease
Chronic alcoholism
20 Chronic heparin administration
Chronic ingestion of anticonvulsant drugs

In addition the invention encompasses the treatment of tumours, especially those related to renal cancer, melanoma, colon cancer, lung cancer and leukemia, viral conditions (for example those involving *Semliki Forest* virus, *Vesicular Stomatitis* virus, 25 *Newcastle Disease* virus, *Influenza A* and *B* viruses, *HIV* virus), ulcers (for example chronic gastritis and peptic ulcer induced by *Helicobacter pylori*), for use as immunosuppressant agents in autoimmune diseases and transplantation, antilipidemic agents for the treatment and/or prevention of hypercholesterolemic and atherosclerotic diseases and to be useful for the treatment of AIDS and Alzheimer's disease. These compounds 30 are also considered useful in treating angiogenic diseases, i.e. those pathological conditions which are dependent on angiogenesis, such as rheumatoid arthritis, diabetic retinopathy, psoriasis and solid tumours.

A compound of formula (I), or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, may be administered *per se* or, preferably, 35 as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.

Accordingly, the present invention also provides a pharmaceutical composition comprising a selective inhibitor of the pharmacological activity of human osteoclast cells,

in particular the bone resorption activity of human osteoclast cells associated with abnormal loss of bone mass, and a pharmaceutically acceptable carrier thereof.

A particular inhibitor of human osteoclast cells is a selective inhibitor of human osteoclast vacuolar ATPase such as a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier thereof.

Active compounds or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof is normally administered in unit dosage form.

An amount effective to treat the disorders hereinbefore described depends upon such factors as the efficacy of the active compounds, the particular nature of the pharmaceutically acceptable salt or pharmaceutically acceptable solvate chosen, the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 0.01 to 50 mg, for example 1 to 25 mg, of the compound of the invention. Unit doses will normally be administered once or more than once a day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 3 or 2 to 4 times a day such that the total daily dose is normally in the range, for a 70 kg adult of 0.01 to 250 mg, more usually 1 to 100 mg, for example 5 to 70 mg, that is in the range of approximately 0.0001 to 3.5 mg/kg/day, more usually 0.01 to 1.5 mg/kg/day, for example 0.05 to 0.7 mg/kg/day.

At the above described dosage range, no toxicological effects are indicated for the compounds of the invention.

The present invention also provides a method for the treatment of tumours, especially those related to renal cancer, melanoma, colon cancer, lung cancer and leukemia, viral conditions (for example those involving *Semliki Forest*, *Vesicular Stomatitis*, *Newcastle Disease*, *Influenza A and B*, *HIV* viruses), ulcers (for example chronic gastritis and peptic ulcer induced by *Helicobacter pylori*), autoimmune diseases and transplantation, for the treatment and/or prevention of hypercholesterolemic and atherosclerotic diseases, AIDS and Alzheimer's disease, angiogenic diseases, such as rheumatoid arthritis, diabetic retinopathy, psoriasis and solid tumours, in a human or non-human mammal, which comprises administering an effective, non-toxic, amount of a compound of formula (I) or a pharmaceutically acceptable solvate thereof, to a human or non-human mammal in need thereof.

In such treatments the active compound may be administered by any suitable route, e.g. by the oral, parenteral or topical routes. For such use, the compound will normally be employed in the form of a pharmaceutical composition in association with a human or

veterinary pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.

5 Compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusible solutions or suspensions, suppositories and transdermal devices. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.

10 Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.

15 Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

20 These solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

25 Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

35 For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a

local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

5 Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.

10 For topical administration, the composition may be in the form of a transdermal ointment or patch for systemic delivery of the active compound and may be prepared in a conventional manner, for example, as described in the standard textbooks such as '*Dermatological Formulations*' - B.W. Barry (Drugs and the Pharmaceutical Sciences - Dekker) or Harrys Cosmetics (Leonard Hill Books).

15 The present invention also provides the use of a selective inhibitor of the biological activity of human osteoclast cells, in particular the bone resorption activity of human osteoclast cells associated with abnormal loss of bone mass, compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of diseases associated with over activity of osteoclasts in mammals, such as the treatment and/or
20 prophylaxis of osteoporosis and related osteopenic diseases.

The present invention also provides the use of a selective inhibitor of the biological activity of human osteoclast cells, in particular the bone resorption activity of human osteoclast cells associated with abnormal loss of bone mass, for the manufacture of a medicament for the treatment of tumours, especially those related to renal cancer,
25 melanoma, colon cancer, lung cancer and leukemia., viral conditions (for example those involving *Semliki Forest*, *Vesicular Stomatitis*, *Newcastle Disease*, *Influenza A and B*, *HIV* viruses), ulcers (for example chronic gastritis and peptic ulcer induced by *Helicobacter pylori*), autoimmune diseases and transplantation, for the treatment and/or prevention of hypercholesterolemic and atherosclerotic diseases, AIDS and Alzheimer's
30 disease, angiogenic diseases, such as rheumatoid arthritis, diabetic retinopathy, psoriasis and solid tumours,.

No unacceptable toxicological effects are expected with compounds of the invention when administered in accordance with the invention. As is common practice, the compositions will usually be accompanied by written or printed directions for use in the
35 medical treatment concerned.

The following, descriptions, examples and pharmacological methods illustrate the invention but do not limit it in any way.

Preparation 1

- 5 **(E)-3-(Benzofuran-2-yl)-prop-2-enal.** A solution of benzofuran-2-carboxaldehyde (2.2 g, 15.1 mmol) and formylmethylenetriphenylphosphorane (4.6 g, 15.1 mmoles) in CH₂Cl₂ (150 mL) was refluxed for 6 hours. Another aliquot of formylmethylenetriphenylphosphorane (1.5 g, 4.93 mmol) was then added and the reflux continued overnight. The reaction mixture was cooled to RT, the solvent concentrated at
10 reduced pressure and the residue was chromatographed on silicagel (n-heptane/EtOAc 4/1). The collected fractions were pooled and concentrated and the residue triturated with isopropyl ether to give, after drying, pure title compound (1.3 g, 7.55 mmol, yield 50.0%) as pale yellow crystals, m.p.=67°.

15 *Example 1*

- Methyl (2Z,4E)-5-(benzofuran-2-yl)-2-methoxy-2,4-pentadienoate.** A suspension of methyl 2-methoxy-2-triphenylphosphonium acetate (4.45 g, 10.0 mmol) and DBU (1.52 g, 10.0 mmol) in CH₂Cl₂ (25 ml) was stirred at RT for 15 minutes. Then (E)-3-(benzofuran-2-yl)-propenal (1.12 g, 6.50 mmol) was added and stirring continued for 3 hours. The
20 reaction mixture was washed with 1N HCl (10 ml), with 5% aqueous NaHCO₃ (10 ml) and brine (2x10 ml). The organic solution was dried (MgSO₄) and concentrated to give an oil that was chromatographed on silicagel (n-heptane/EtOAc 4/1). The pooled fractions were collected and concentrated to give pure title compound (1.05 g, 4.07 mmol, yield 62.5%) as pale yellow crystals, m.p.=108°.
- 25 ¹H-NMR (CDCl₃): 7.54 (d, 1H); 7.48 (d, 1H); 7.16-7.40 (m, 3H); 6.87 (d, 1H); 6.73 (s, 1H); 6.69 (d, 1H); 3.84 (s, 6H).

Example 2

- (2Z,4E)-5-(Benzofuran-2-yl)-2-methoxy-2,4-pentadienoic acid. To a stirred solution of methyl (2Z,4E)-5-(benzofuran-2-yl)-2-methoxy-2,4-pentadienoate (1.0 g, 3.87 mmol) in EtOH/water 1/1 (80 ml) potassium hydroxide (0.43 g, 7.66 mmol) was added. The solution was refluxed for 1 hour, then it was cooled to RT and poured into water (200 ml). After acidification to pH 2 (1N HCl) the resulting suspension was extracted with EtOAc (3x50 ml). The organic phase was washed with water (2x30 ml), dried (MgSO₄) and concentrated to give a yellow solid. This was repeatedly washed with CH₂Cl₂ and dried to give the pure title compound (0.80 g, 3.28 mmoles, yield 84.6%) as yellow crystals, m.p.=206°.
- ¹H-NMR (DMSO-d₆): 12.90 (bs, 1H); 7.60 (bs, 2H); 7.10-7.32 (m, 4H); 7.02 (s, 1H); 6.88 (t, 1H); 3.73 (s, 3H).

Example 3

- (2Z,4E)-5-(Benzofuran-2-yl)-2-methoxy-N-((2,2,6,6-tetramethyl)-piperidin-4-yl)-2,4-pentadienamide. A solution of (2Z,4E)-5-(benzofuran-2-yl)-2-methoxy-2,4-pentadienoic acid (122 mg, 0.5 mmol), 4-amino-2,2,6,6-tetramethylpiperidine (78 mg, 0.5 mmol), 1-hydroxy-7-azabenzotriazole hydrate (65 mg, 0.5 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (95 mg, 0.5 mmol) in DMF (2 ml) was stirred at RT for 6 hours. The solution was poured into brine (20 ml) and repeatedly extracted with EtOAc. The organic phase was washed with 5% aqueous CaCO₃, dried (MgSO₄) and concentrated to give a solid that was repeatedly washed with isopropyl ether. After drying pure title compound (45 mg, 0.12 mmol, yield 23.5%) was obtained as pale yellow crystals, m.p.=250°dec.
- ¹H-NMR (DMSO-d₆): 9.33 (bs, 1H); 8.35 (d, 1H); 7.60 (t, 2H); 7.24-7.36 (m, 2H); 7.15 (dd, 1H); 7.00 (s, 1H); 6.90 (d, 1H); 6.63 (d, 1H); 4.21 (m, 1H); 3.71 (s, 3H); 1.83 (bd, 2H); 1.67 (bt, 2H); 1.43 (s, 12H).

Example 4

(2Z,4E)-5-(Benzofuran-2-yl)-2-methoxy-N-(3-diethylaminopropyl)-2,4-

pentadienamide. A solution of (2Z,4E)-5-(benzofuran-2-yl)-2-methoxy-2,4-pentadienoic acid (122 mg, 0.5 mmol), 3-diethylaminopropylamine (65 mg, 0.5 mmol), 1-hydroxy-7-azabenzotriazole hydrate (65 mg, 0.5 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (95 mg, 0.5 mmol) in DMF (2 ml) was stirred at RT overnight. After the same work-up described in *example 3* the residue was chromatographed on silicagel (preparative TLC, EtOAc/MeOH/aq.NH₃ 8/2/1). The fraction collected was dried to give pure title compound (32 mg, .090 mmol, yield 18.0%) as pale brown crystals, m.p.=79°.

- 15 ¹H-NMR (DMSO-d₆): 8.37 (bt, 1H); 7.61 (t, 2H); 7.21-7.34 (m, 2H); 7.15 (dd, 1H); 7.00 (s, 1H); 6.90 (d, 1H); 6.66 (d, 1H); 3.72 (s, 3H); 3.20 (q, 2H); 2.46 (bm, 6H); 1.60 (bt, 2H); 0.96 (t, 6H).

Preparation 2:

- 15 **1,2,2,6,6-Pentamethyl-4-piperidone hydroiodide.** A solution of 2,2,6,6-tetramethyl-4-piperidone monohydrate (40 g, 23.1 mmol) and methyl iodide (98.31 g, 69.3 mmol) in isopropyl alcohol (25 mL) was stirred at RT for 48 h. The resulting suspension was filtered, the solid residue was dried and recrystallized from MeOH. After filtration and repeated washings with MeOH the solid was dried giving pure title compound (31.6 g, 20 10.6 mmol, yield 46.0%) as pale brown crystals.

Preparation 3:

- 25 **1,2,2,6,6-Pentamethyl-4-piperidone oxime.** A suspension of 1,2,2,6,6-pentamethyl-4-piperidone hydroiodide (3 g, 10.1 mmol) and hydroxylamine hydrochloride (980 mg, 14 mmol) in water (6 ml) was stirred at RT for 15 min. Solid NaOH was added until basic pH and thickening of the suspension. Water (3 ml) was added and stirring at RT was continued overnight. The suspension was filtered and the solid washed with water (few ml) and dried. The solid was then dissolved in Et₂O, the solution was dried (MgSO₄) and

concentrated to give after drying pure title compound (1.55 g, 8.41 mmol, yield 83.3%) as white crystals.

Preparation 4

- 5 **4-Amino-1,2,2,6,6-pentamethyl-4-piperidine.** LiAlH₄ (925 mg, 24.4 mmol) was added under stirring at 0° under Ar to anhydrous THF (100 ml), followed by 1,2,2,6,6-pentamethyl-4-piperidone oxime (1.50 g, 8.14 mmol). The suspension was refluxed for 2 hours, then cooled to RT and stirred overnight. After cooling to 0° water (0.9 ml), 15% aqueous NaOH (0.9 ml) and water (2.8 ml) were carefully added dropwise. The
10 suspension was stirred for 15 min at RT, then MgSO₄ was added and stirring continued for 30 min. After filtration, the liquid was concentrated and the oily residue chromatographed on silicagel (CH₂Cl₂/MeOH/aq.NH₃ 95/5/1). The collected fractions were pooled and concentrated to give pure title compound (750 mg, 4.40 mmol, yield 54.1%) as a yellow oil.

15

Example 5

- (2Z,4E)-5-(Benzofuran-2-yl)-2-methoxy-N-[(1,2,2,6,6-pentamethyl)-piperidin-4-yl]-2,4-pentadienamide. A solution of (2Z,4E)-5-(benzofuran-2-yl)-2-methoxy-2,4-pentadienoic acid (122 mg, 0.5 mmol), 4-amino-1,2,2,6,6-pentamethylpiperidine (85 mg, 0.5 mmol), 1-hydroxy-7-azabenzotriazole hydrate (65 mg, 0.5 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (95 mg, 0.5 mmol) in DMF (2 ml) was stirred at RT overnight. After the same work-up described in *example 3* the residue was triturated with isopropyl ether to produce a solid that was recovered and dried to give pure title compound (85 mg, 0.214 mmol, yield 42.8%) as yellow crystals,
20 m.p.=152°.

25

¹H-NMR (DMSO-d₆): 8.07 (bd, 1H); 7.61 (t, 2H); 7.22-7.36 (m, 2H); 7.14 (dd, 1H); 7.00 (s, 1H); 6.89 (d, 1H); 6.60 (d, 1H); 4.10 (m, 1H); 3.71 (s, 3H); 2.27 (s, 3H); 1.50-1.72 (bm, 4H); 1.12 (d, 12H).

Preparation 5

5-Chlorobenzofuran-2-carboxylic acid. A suspension of 5-chlorosalicyl aldehyde (10.62 g, 67.8 mmol), ethyl bromomalonate (25.3 g, 105.8 mmol) and anhydrous potassium carbonate (9.37 g, 67.8 mmol) in ethylmethylketone (50 ml) was refluxed for 5 hours, then kept under stirring at RT overnight. The solvent was evaporated and the residue was diluted with water (500 ml), then the pH was neutralized with 1N HCl. The suspension was extracted with Et₂O, then the organic phase was dried (MgSO₄) and concentrated. The oily residue was dissolved in absolute EtOH (50 ml) and added to a 10% ethanolic solution of KOH. The thick suspension was refluxed under vigorous stirring overnight then after cooling to RT the solvent was taken off and water was added. The aqueous phase was washed with Et₂O, then the pH adjusted to 2 with 1N HCl. The aqueous suspension was extracted with EtOAc and the organic phase after drying (MgSO₄) and concentration produced pure title compound (7.4 g, 37.6 mmol, yield 55.5%) as a yellow oil.

Preparation 6

5-Chlorobenzofuran-2-carboxaldehyde. LiAlH₄ (3.04 g, 80 mmol) was suspended under stirring at 0° under Ar in anhydrous THF (150 ml), then N-methylpiperazine dihydrochloride (6.92 g, 40 mmol) was added portionwise in 10 minutes. N-methylpiperazine (12 g, 120 mmol) was then added dropwise, the mixture was warmed to RT and stirring continued for 2 hours. The supernatant of this suspension was then added by syringe to a stirred solution at 0° under Ar of 5-chlorobenzofuran-2-carboxylic acid (2.95 g, 15.0 mmol) in anhydrous THF (50 ml). The mixture was refluxed for 4 hours and after cooling to RT the suspension was diluted with Et₂O (400 ml). The resulting mixture was poured into water (500 ml) and the organic phase was decanted. The aqueous phase was extracted with Et₂O (2x300 ml) and the pooled organic extracts were washed with 2N NaOH (200 ml), 1N HCl (200 ml) and brine (200 ml). After drying (MgSO₄) and concentration a brown oily residue was obtained. This was chromatographed on silicagel (n-heptane/EtOAc 3/1). The pooled fractions produced after evaporation pure title compound (850 mg, 4.71 mmol, yield 31.4%) as brown needles.

Preparation 7

(E)-3-(5-Chlorobenzofuran-2-yl)-prop-2-enal. A solution of 5-chlorobenzofuran-2-carboxaldehyde (813 mg, 4.50 mmol) and fomylmethylene triphenylphosphorane (1.37 g, 4.50 mmol) in CH₂Cl₂ (40 ml) was treated as seen in *preparation 1*. After a chromatography on silicagel (n-heptane/EtOAc 4/1) pure title compound (640 mg, 3.10 mmol, yield 68.8%) as yellow crystals was obtained.

Example 6

10 **Methyl (2Z,4E)-5-(5-chlorobenzofuran-2-yl)-2-methoxy-2,4-pentadienoate.** A suspension of methyl 2-methoxy-2-triphenylphosphonium acetate (1.80 g, 4.04 mmol) and DBU (610 mg, 4.04 mmol) in CH₂Cl₂ (20 ml) was stirred at RT for 15 minutes. Then (2E)-3-(5-chlorobenzofuran-2-yl)-propenal (465 mg, 2.25 mmol) was added and the reaction conducted as seen for *example 1*. After a chromatography on silicagel (n-heptane/EtOAc 4/1) pure title compound (550 mg, 1.78 mmol, yield 79.2%) as yellow crystals was obtained.

¹H-NMR (DMSO-d₆): 7.70 (d, 1H); 7.65 (d, 1H); 7.36 (dd, 1H); 7.20 (dd, 1H); 7.05 (s, 1H); 6.97 (d, 1H); 6.91 (d, 1H); 3.77 (s, 3H); 3.74 (s, 3H).

20 *Example 7*

(2Z,4E)-5-(5-Chlorobenzofuran-2-yl)-2-methoxy-2,4-pentadienoic acid. To a stirred solution of methyl (2Z,4E)-5-(5-chlorobenzofuran-2-yl)-2-methoxy-2,4-pentadienoate (530 mg, 1.81 mmol) in EtOH/water 1/1 (40 ml) potassium hydroxide (0.43 g, 7.66 mmol) was added. The solution was stirred at RT overnight, then it was treated as seen in *example 2*. Pure title compound (330 mg, 1.18 mmol, yield 65.4%) was obtained as bright yellow crystals.

¹H-NMR (DMSO-d₆): 7.68 (d, 1H); 7.63 (d, 1H); 7.33 (d, 1H); 7.20 (dd, 1H); 6.97 (s, 1H); 6.90 (d, 1H); 6.73 (d, 1H); 3.75 (s, 3H).

Example 8

(2Z,4E)-5-(5-Chlorobenzofuran-2-yl)-2-methoxy-N-((1,2,2,6,6-pentamethyl)-piperidin-4-yl)-2,4-pentadienamide. A solution of (2Z,4E)-5-(5-chlorobenzofuran-2-yl)-2-methoxy-2,4-pentadienoic acid (88 mg, 0.32 mmol), 4-amino-1,2,2,6,6-pentamethylpiperidine (60 mg, 0.35 mmol), 1-hydroxy-7-azabenzotriazole hydrate (44 mg, 0.32 mmol) and 1-(3-dimethylamino propyl)-3-ethylcarbodiimide hydrochloride (62 mg, 0.5 mmol) in DMF (2 ml) was stirred at RT for 6 hours. After the same work up as seen in *example 3* pure title compound was obtained (55 mg, .128 mmol, yield 40.0%) as bright yellow crystals, m.p.=142°.

¹H-NMR (DMSO-d₆): 8.01 (d, 1H); 7.69 (d, 1H); 7.63 (d, 1H); 7.33 (dd, 1H); 7.18 (dd, 1H); 6.98 (s, 1H); 6.89 (d, 1H); 6.57 (d, 1H); 4.08 (m, 1H); 3.71 (s, 3H); 2.18 (s, 3H); 1.61 (dd, 2H); 1.44 (dd, 2H); 1.05 (d, 12H).

Example 9

(2Z,4E)-5-(5-Chlorobenzofuran-2-yl)-N-(3-diethylaminopropyl)-2-methoxy-2,4-pentadienamide. A solution of (2Z,4E)-5-(5-chlorobenzofuran-2-yl)-2-methoxy-2,4-pentadienoic acid (88 mg, 0.32 mmol), 3-dimethylamino propylamine (46 mg, 0.35 mmol), 1-hydroxy-7-azabenzotriazole hydrate (44 mg, 0.32 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (62 mg, 0.5 mmol) in DMF (2 ml) was stirred at RT for 6 hours. After the same work up as seen in *example 3* pure title compound was obtained (60 mg, .153 mmol, yield 48.0%) as yellow crystals, m.p.=150°dec.

¹H-NMR (DMSO-d₆): 8.42 (t, 1H); 7.70 (d, 1H); 7.63 (d, 1H); 7.34 (dd, 1H); 7.18 (dd, 1H); 6.99 (s, 1H); 6.91 (d, 1H); 6.66 (d, 1H); 3.73 (s, 3H); 3.25 (bq, 2H); 2.66 (bt, 6H); 1.68 (bt, 2H); 1.04 (t, 6H).

Preparation 8

Benzothiophen-2-carboxaldehyde. LiAlH₄ (7.6 g, 200 mmol) was suspended under stirring at 0° under Ar in anhydrous THF (400 ml), then N-methylpiperazine dihydrochloride (17.3 g, 100 mmol) was added portionwise in 10 min. N-methylpiperazine (30 g, 300 mmol) was then added dropwise, the mixture was warmed to RT and stirring
5 continued for 2 hours. The supernatant of this suspension was then added by syringe to a stirred solution at 0° under Ar of benzothiophen-2-carboxylic acid (7.13 g, 40.0 mmol) in anhydrous THF (200 ml). The mixture was refluxed for 4 hours and after the same procedure as in *preparation 6* pure title compound was obtained (4.6 g, 28.4 mmol, yield 70.9%) as dark orange crystals.

10

Preparation 9

(2E)-3-(Benzothiophen-2-yl)-2-propenal. A solution of benzothiophene-2-carboxaldehyde (3 g, 18.4 mmol) and formylmethylenetriphenylphosphorane (5.62 g, 18.4 mmol) in CH₂Cl₂ (100 ml) was treated as seen in *preparation 1*. After a chromatography
15 on silicagel (n-heptane/EtOAc 4/1) pure title compound was obtained (1.00 g, 5.31 mmol, yield 28.9%) as yellow crystals, m.p.=88°.

Example 10

Methyl (2Z,4E)-5-(benzothiophen-2-yl)-2-methoxy-2,4-pentadienoate. A suspension
20 of methyl 2-methoxy-2-triphenylphosphonium acetate (4.72 g, 10.6 mmol) and DBU (1.62 g, 10.6 mmol) in CH₂Cl₂ (50 ml) was stirred at RT for 15 minutes. Then (2E)-3-(benzothiophen-2-yl)-2-propenal (1.0 g, 5.31 mmol) was added and the reaction conducted as seen for *example 1*. After a chromatography on silicagel (n-heptane/EtOAc 4/1) pure title compound was obtained (107 mg, 0.39 mmol, yield 7.3%) as yellow
25 crystals.

¹H-NMR (DMSO-d₆): 7.66-7.81 (m, 3H); 7.27-7.34 (m, 2H); 7.20 (s, 1H); 6.87 (d, 1H); 6.05 (d, 1H); 3.91 (s, 3H); 3: 7.5 (s, 3H).

Example 11

(2Z,4E)-5-(Benzothiophen-2-yl)-2-methoxy-2,4-pentadienoic acid. To a stirred solution of methyl (2Z,4E)-5-(benzothiophen-2-yl)-2-methoxy-2,4-pentadienoate (107 mg, 0.39 mmol) in EtOH/water 1/1 (10 ml) potassium hydroxide (47 mg, 0.78 mmol) was added. The solution was refluxed for 1 hour, then it was treated as seen in *example 2*. Pure title compound (54 mg, .207 mmol, yield 53.2%) was obtained as yellow crystals.

¹H-NMR (DMSO-d₆): 7.89 (m, 1H); 7.76 (m, 1H); 7.62 (dd, 1H); 7.38 (s, 1H); 7.31-7.38 (m, 2H); 7.04 (d, 1H); 6.22 (d, 1H); 3.66 (s, 3H).

Example 12

(2Z,4E)-5-(Benzothiophen-2-yl)-2-methoxy-N-[(1,2,2,6,6-pentamethyl)-piperidin-4-yl]-2,4-pentadienamide. A solution of (2Z,4E)-5-(benzothiophen-2-yl)-2-methoxy-2,4-pentadienoic acid (53 mg, .20 mmol), 4-amino-1,2,2,6,6-pentamethylpiperidine (34 mg, 0.20 mmol), 1-hydroxy-7-azabenzotriazole hydrate (27 mg, 0.20 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (38 mg, 0.20 mmol) in DMF (1 ml) was stirred at RT for 6 hours. After the same work up as seen in *example 3* pure title compound was obtained (22 mg, .054 mmol, yield 26.6%) as white crystals, m.p.=240°.

¹H-NMR (DMSO-d₆): 7.73-7.94 (m, 4H); 7.33 (bs, 3H); 6.91 (d, 1H); 5.99 (d, 1H); 3.67 (s, 3H); 2.18 (s, 3H); 1.62 (bd, 2H); 1.42 (bt, 2H); 1.06 (d, 12H).

Preparation 10

(E)-3-(3-Methylbenzothiophen-2-yl)-2-propenal. 3-Methylbenzo[b]thiophene-2-carboxaldehyde (4.2 g, 23.8 mmol) was dissolved in dry toluene (100 ml) and treated with (formylmethylene)triphenylphosphorane (7.35 g, 24.2 mmol). The reaction mixture was heated to 80°C for 10 hours, allowed to cool and the residue was washed with 200 ml of hexane/Et₂O 1/1 and then triturated with isopropyl ether to give pure title compound (2.5g, 12.38 mmol, yield 52.0%), m.p.=90-92°C.

Example 13

Methyl (2Z,4E)-2-methoxy-5-(3-methylbenzothiophen-2-yl)-2,4-pentadienoate and methyl (2E,4E)-2-methoxy-5-(methylbenzothiophen-2-yl)-2,4-pentadienoate. A solution of (E)-3-[2-(3-methylbenzothiophen-2-yl)]-2-propenal (1 g, 5 mmol) in CH₂Cl₂ (30 ml) under nitrogen was treated with methoxycarbonylmethyl-2-methoxy triphenylphosphonium bromide (4.45 g, 10 mmol) and DBU (1.5 ml, 10 mmol). The reaction mixture was stirred at room temperature for 2 hours, washed with 10% aqueous HCl (5 ml), saturated solution of NaHCO₃ (5 ml) and brine (5 ml), dried over Na₂SO₄ and evaporated under vacuum. The residue was purified by chromatography on silicagel (hexane/EtOAc 7/3) to afford, after trituration with isopropyl ether, methyl (2Z,4E)-2-methoxy-5-(3-methylbenzothiophen-2-yl)-2,4-pentadienoate (380 mg, 1.32 mmol, yield 26.3%), m.p.= 106-107°C, and methyl (2E,4E)-2-methoxy-5-(methylbenzothiophen-2-yl)-2,4-pentadienoate, (13 mg, .050 mmol, yield 1.0%), m.p.= 91-92°C.

Methyl (2Z,4E)-2-methoxy-5-(3-methylbenzothiophen-2-yl)-2,4-pentadienoate: ¹H-NMR (acetone-d₆): 7.84 (m, 1H); 7.75 (m, 1H); 7.45-7.35 (m, 3H); 7.00 (d, 1H); 6.92 (d, 1H); 3.80 (s, 6H); 2.48 (s, 3H)

Methyl (2E,4E)-2-methoxy-5-(3-methylbenzothiophen-2-yl)-2,4-pentadienoate: ¹H-NMR (acetone-d₆): 7.81 (m, 1H); 7.71 (dd, 1H); 7.69 (m, 1H); 7.40-7.31 (m, 2H); 7.18 (d, 1H); 6.32 (d, 1H); 3.82 (s, 3H); 3.72 (s, 3H); 2.44 (s, 3H)

Preparation 11

(2E)-3-(Quinolin-2-yl)-prop-2-enal. A solution of quinolin-2-carboxaldehyde (3.5 g, 22.3 mmol) and formylmethylenetriphenylphosphorane (6.79 g, 22.3 mmol) in CH₂Cl₂ (180 ml) was treated as seen in *preparation 1*. After a chromatography on silicagel (n-heptane/EtOAc 4/1) pure title compound was obtained (460 mg, 2.51 mmol, yield 11.3%) as grey needles, m.p.=85°.

Example 14

Methyl (2Z,4E)-5-(quinolin-2-yl)-2-methoxy-2,4-pentadienoate. A suspension of methyl 2-methoxy-2-triphenylphosphonium acetate (2.22 g, 5.0 mmol) and DBU (750 mg, 5.0 mmol) in CH₂Cl₂ (20 ml) was stirred at RT for 15 minutes. Then (2E)-3-(quinolin-2-yl)-propenal (460 mg, 2.51 mmol) was added and the reaction conducted as seen for *example 1*. After a chromatography on silicagel (n-heptane/EtOAc 4/1) pure title compound was obtained (450 mg, 1.67 mmol, yield 66.6%) as brown crystals, m.p.=88°.

¹H-NMR (200MHz, d₆DMSO): 8.36 (d, 1H); 7.99 (t, 2H); 7.72-7.84 (m, 3H); 7.60 (dd, 1H); 7.23 (d, 1H); 6.98 (d, 1H); 3.79 (s, 3H); 3.78 (s, 3H)

10 **LIST OF ABBREVIATIONS USED IN THE ABOVE PREPARATIONS AND EXAMPLES**

Celite	Registered trade mark for dicalite
DMF	Dimethylformamide
EI	Electron Impact
AcOEt	Ethyl acetate
FAB POS	Fast Atom Bombardment / Positive ions detection
MS	Mass Spectrum
THF	Tetrahydrofuran
TSP	ThermoSpray

Biological Assays

Background. It is known that, upon attachment to bone, an electrogenic H^+ - adenosine triphosphatase (ATPase) is polarised to the osteoclast-bone interface. The pump
5 transports massive quantities of protons into the resorption microenvironment to effect mobilisation of the bone mineral and to create the acidic pH required by collagenases to degrade the bone matrix.

The vacuolar nature of the osteoclast proton pump was originally recognised by Blair [H. C. Blair et al., *Science*, **245**, 855 (1989)] and then confirmed by Bekker [P.J. Bekker et al., *J. Bone Min. Res.*, **5**, 569 (1990)] and Väänänen [K.K. Väänänen et al., *J. Cell. Biol.*, **111**, 1305 (1990)]. Evidence was based upon preparations of ruffled
10 membrane fragments from avian osteoclasts (obtained from the medullar bone of calcium-starved egg-laying hens). The resulting membrane vesicles acidify in response to ATP, which is easily assessed by measuring the fluorescence quench of acridine orange, a weak
15 base which accumulates into acidic compartments.

The biochemical pattern indicated that the osteoclast proton pump belonged to the vacuolar-like ATPases since proton transport was inhibited by N-ethylmaleimide (NEM), a sulphhydryl reagent, and by bafilomycin A₁, a selective inhibitor of vacuolar H^+ -ATPases [J.E. Bowman et al., *Proc. Natl. Acad. Sci. USA*, **85**, 7972 (1988)], whilst it was not
20 inhibited by ouabain, an inhibitor of Na^+/K^+ -ATPases; sodium orthovanadate, an inhibitor of p-ATPases, or by omeprazole or SCH 28080, both of which are inhibitors of gastric H^+/K^+ -ATPase [J.P. Mattson et al., *Acta Physiol. Scand.*, **146**, 253 (1992)].

It is known that specific inhibitors of vacuolar ATPases, such as bafilomycin A₁, are able to inhibit bone resorption in osteoclast cultures [K. Sundquist et al., *Biochem. Biophys. Res. Commun.*, **168**, 309-313 (1990)]
25

INHIBITION OF v-ATPase PROTON TRANSPORT IN MEMBRANE VESICLES

Preparation of crude bone microsomes from calcium-starved egg-laying hens.

Vesicles were prepared from medullar bone obtained from tibiae and femurs of egg-laying
30 hens which were calcium-starved for at least 15 days. Briefly, bone fragments were scraped with a 24 scalpel blade, suspended in 40 ml of isolation medium (0.2 M sucrose, 50 mM KCl, 10 mM Hepes, 1 mM EGTA, 2 mM dithiothreitol, pH 7.4) and filtered through a 100 µm pore size nylon mesh. The whole procedure was performed at 4°C. After homogenisation in a potter (20 strokes) in 40 ml of isolation medium an initial

centrifugation ($6,500 \times g_{\max} \times 20 \text{ min}$) was performed to remove mitochondria and lysosomes. The supernatant was centrifuged at $100,000 \times g_{\max}$ for 1 hr and the pellet was collected in 1 ml of isolation medium, divided into 200 μl aliquots, immediately frozen in liquid nitrogen and stored at -80°C . The protein content was determined using a Biorad colourimetric kit according to Bradford [M. Bradford, *Anal. Biochem.*, **72**, 248 (1976)].
5 For the proton transport assay, 5-10 μl of membranes were used.

Purification of osteoclast membranes. 1 ml of crude microsomal vesicles prepared above were applied (about 0.2 ml per tube) on the top of a sucrose step-gradient consisting of
10 3.5 ml of 15%, 30% and 45 % (w/w) sucrose in isolation medium and centrifuged at $280,000 g_{\max}$ for 2 hours (SW 41 Ti rotor). After centrifugation the 30-45% sucrose interfaces were collected, diluted approx. 20-fold in isolation medium and pelleted at $100,000 g_{\max}$ for 1 hour (SW 28 rotor). The pellet was then resuspended in 1 ml of isolation medium, aliquoted and frozen in liquid N_2 and stored at -80°C until used.

Proton transport in membrane vesicles was assessed, semi-quantitatively, by measuring the initial slope of fluorescence quench of acridine orange (excitation 490 nm; emission 530) after addition of 5-20 μl of membrane vesicles in 1 ml of buffer containing 0.2 M sucrose, 50 mM KCl, 10 mM Hepes pH 7.4, 1 mM ATP.Na_2 , 1 mM CDTA, 5 μM valinomycin and 4 μM acridine orange. The reaction was started by addition of 5 mM MgSO_4 . Results were expressed as the percent of the mean of two controls.
20

Inhibition of bafilomycin-sensitive ATPase activity was assessed in purified membrane vesicles by measuring the release of inorganic phosphate (Pi) during 30 min of incubation at 37°C in a 96-well plate either in the presence or in the absence of bafilomycin A1. The
25 reaction medium contained 1 mM ATP, 10 mM HEPES-Tris pH 8, 50 mM KCl, 5 μM valinomycin, 5 μM nigericin, 1 mM CDTA-Tris, 100 μM ammonium molybdate, 0.2 M sucrose and membranes (20 μg protein/ml). The reaction was initiated by MgSO_4 (8-arm pipette) and stopped, after 30 min, by addition of 4 volumes of the malachite green
30 reagent (96-arm pipette) prepared according to Chan [*Anal. Biochem.* **157**, 375 (1986)]. Absorbance at 650 nm was measured after 2 min using a microplate reader. Results are expressed as $\mu\text{mol} (\text{Pi}) \times \text{mg protein}^{-1} \times \text{hour}^{-1}$ and, for each experiment, represent the mean \pm sem of triplicates.

PHARMACOLOGICAL DATA:

INHIBITION OF BAFILOMYCIN-SENSITIVE ATPASE IN CHICKEN OSTEOCLASTS

5

Ex. No	IC ₅₀ (μM) ATPase assay
3	8.6
5	11
8	0.5
9	10
12	10.6

INHIBITION OF BONE RESORPTION

In Vitro assays

- 1) Bone resorption can be assessed as described previously in the literature [T. J. Chambers et al., *Endocrinology*, **1985**, *116*, 234]. Briefly, osteoclasts were mechanically disaggregated from neonatal rat long bones into Hepes-buffered medium 199 (Flow, UK). The suspension was agitated with a pipette, and the larger fragments were allowed to settle for 30 sec. The cells were then added to two wells of a multiwell dish containing bone slices (each measuring 12 mm²). After 15 min at 37°C the bone slices were removed, washed in medium 199 and placed in individual wells of a 96-well plate. These were incubated for 24 hrs in a total volume of 2 ml of culture medium, consisting of 10% foetal calf serum in Hanks-buffered MEM, in the presence or absence of drug. The number of osteoclasts and bone resorption were quantified by confocal laser scanning microscopy (CLSM): the bone slices were fixed with 2% glutaraldehyde in 0.2 M cacodylate buffer and the osteoclasts on each bone slice were stained for tartrate-resistant acid phosphatase. After counting the number of large, multinucleated, red-stained cells, the bone slices were immersed in 10% sodium hypochlorite for 60 min to remove cells, washed in distilled water and sputter-coated with gold. The entire surface of each bone slice was then examined in CLSM. The number and the size of the osteoclastic excavations, the plain area and the volume of bone resorbed was recorded. Results were expressed as mean pit number per osteoclast, mean area per osteoclast or mean volume per osteoclast.

2) **Inhibition of PTH-stimulated $^{45}\text{Ca}^{2+}$ release from pre-labelled foetal rat long bone.** The assay is based on that described by Raisz (*J. Clin. Invest.* 44:103-116, 1965). Time-mated Sprague-Dawley rats were injected subcutaneously with 200 mCi of $^{45}\text{CaCl}_2$ on the 18th day of gestation. On the following day, the foetuses were removed aseptically and the radii and ulnae were dissected free of adjacent soft tissue and the cartilaginous ends, and then cultured for 24 hr at 37°C in BGJ medium containing 1 mg/ml BSA. The bones were then transferred to fresh medium containing the test compounds (0.1 - 50 μM) with and without PTH (12 nM) and were incubated for an additional 48 hr. The media were collected and the bones extracted to determine the mean % calcium release by scintillation counting. Results were expressed as the % inhibition compared to the amount of calcium released from cultures incubated with PTH alone

In vivo assays

Prevention of retinoid-induced hypercalcaemia. The method used was that described by Trechsel et al., (*J. Clin. Invest.* 80:1679-1686, 1987). Briefly, male Sprague-Dawley rats weighing 160-200 g (10 per group) were thyroparathyroidectomised and were treated subcutaneously with the retinoid Ro 13-6298 (30 $\mu\text{g/day}$) for three days and this was found to significantly increase blood serum calcium by 4-5 mg/100 ml. For inhibition of this effect, rats were treated simultaneously with test compounds i.v. or p.o. at 0.1 - 100 mg/kg, or vehicle and blood calcium was measured as described above, before treatment and one day after the last administration. Results were expressed as % inhibition with respect to vehicle-treated animals.

Prevention of bone loss in osteoporosis induced by ovariectomy and immobilisation. Seven groups of 10 Sprague-Dawley rats (200 g) underwent ovariectomy plus neurectomy of the sciatic nerve in the right hind limb, while one group was sham-operated according to the method described by Hayashi et al., (*Bone* 10:25-28, 1989). It was demonstrated that a steady-state was attained in the amount of trabecular bone lost 6-12 weeks after the operations. During a 6-week period, the operated animals received the test compounds (0.1 - 100 mg/kg p.o. u.i.d.), or vehicle. At the end of this treatment period, the animals were sacrificed and the tibia and femur of the hind limb removed. The tibia wet and dry weight were determined, and the density (displacement of water) and ashes content (total

weight, calcium and phosphorous content) also measured. The femur were fixed in 10% formalin, de-mineralised in 5% formic acid and the coronal midshaft and longitudinal section of the distal metaphysis cut and stained with haematoxinilin and eosin.

Histomorphometric evaluation was made using a semi-automated image analyser

- 5 (Immagini & Computer, Milan, Italy). In the distal metaphysis, the % trabecular bone area in the secondary spongiosa (which is the trabecular bone 1 mm from the epiphyseal growth plate to about 4 mm towards the midshaft giving a total area of 5 mm²) and the number of trabeculae (according to Parfitt et al., *J. Bone Min. Res.* 2: 595, (1987)) were determined in all animals. In the midshaft, the medullary, cortical (CA) and total (TA)
- 10 cross-sectional area was measured and the cortical index (CI) determined from the formula $CI = CA/TA$.

- Prevention of bone loss in ovariectomised mature rats.** The methodology employed is based on that described by Wronsky et al. [*J. Bone Min. Res.*, 6, 387 (1991)]. The bone
- 15 loss, prevalently cancellous, occuring after the surgery is monitored by dual emission X-ray absorptiometry (DEXA) measurements of bone mineral density (BMD) of long bones and by HPLC measurements of urinary levels of products of bone collagen breakdown, such as the cross-link residues pyridinoline (PYD), deoxypyridinoline (DPD) and lysine glycosides, *i.e.* galactosyl-hydroxylysine (GHYL) and glucosyl-galactosyl-hydroxylysine (GGHYL).
- 20

- Groups of 7-10 female Sprague-Dawley rats, about 90 days old and weighing 200-250 g are used. Rats are anesthetised by sodium pentobarbital (35 mg/kg i.v.), laparotomy is performed and ovaries are bilaterally removed. Wounds are adequately disinfected and sutured. A group is sham operated. During a 4-week experimental period, the operated
- 25 animals receive test compounds in the appropriate vehicle (0.1-100 mg/kg p.o. u.i.d.) or vehicle alone.

Twenty-four-hr urine samples are collected for PYD, DPD, GHYL and GGHYL determinations before and 2, 4, 8, 11, 15, 18, 22 and 25 days after surgery. The aliquots of urine are frozen and stored at -20° C until HPLC analysis.

- 30 Before and at the end of the experimental period, the bone metaphyseal mineral densities of left distal femur and proximal tibia were evaluated *in vivo* using lightly anaesthetised animals. Results are expressed as % of prevention *versus* vehicle treated animals.


OTHER THERAPEUTIC UTILITIES:

The activity of the compounds of the invention for the other utilities mentioned herein may be determined by according to the following methods which are incorporated herein:

1. Antitumor activity may be determined according to the methods disclosed in published International Application, Publication number 93/18652; in particular the screen employed,
5 experimental details and bibliography of M.R. Boyd et al., *Status of the NCI preclinical antitumor drug discovery screen; principles and practices of Oncology*, 3, issue 10, Oct. 1989, Lippincott.
2. Antiviral activity may be assessed using the *in vitro* assays reported by H. Ochiai et al., *Antiviral Research*, 27, 425-430 (1995) or by C. Serra et al., *Pharmacol. Res.*, 29, 359
10 (1994). Anti-HIV activity can be assessed as reported in the literature, for example by S. Velásquez et al., *J. Med. Chem.*, 38, 1641-1649 (1995)
3. Antiulcer activity may be assessed *in vivo* using the methods reported in the literature, for example, as described by C.J. Pfeiffer, *Peptic Ulcer*, C.J. Pfeiffer Ed., Munksgaard Publ., Copenhagen, 1971. *In vitro* assays for inhibition of vacuolization induced by
15 *Helicobacter pylori* are described, for example, by E. Papini et al., *FEMS Microbiol. Lett.*, 113, 155-160 (1993)
4. Usefulness in treating Alzheimer's disease may be determined using models *in vitro* such as inhibition of amiloyd- β production as described in the literature by J. Knops et al., *J. Biol. Chem.*, 270, 2419-2422 (1995) or by models *in vivo*: such as the transgenic
20 mouse model overexpressing human APP reported by D. Games et al., *Nature*, 373, 523-527 (1995).
5. Immunosuppressant activity can be assessed as reported in the literature, for example by M.-K. Hu et al., *J. Med. Chem.*, 38, 4164-4170 (1995)
6. Antilipidemic activity can be assessed as reported in the literature, for example by E.A.L. Biessen et al., *J. Med. Chem.*, 38, 1846-1852 (1995). Antiatherosclerotic activity may be
25 assessed by using animal models of atherosclerosis, such as the atherosclerotic rabbit model, which are reported in the literature, for example by R.J. Lee et al., *J. Pharm. Exp. Ther.*, 184, 105-112 (1973).
7. Angiostatic activity may be assessed using the methods reported in the literature, for
30 example as described by T. Ishii et al., *J. Antibiot.*, 48, 12 (1995).


Claims:

1. A compound of formula (I):



(I)

- 5 or a salt thereof, or a solvate thereof, wherein:
 R_1 represents an alkyl group or a substituted or unsubstituted aryl group;
 R_2 , R_3 and R_4 each independently represent hydrogen, alkyl, aryl or substituted aryl;
 R_5 and R_6 each independently represents hydrogen, hydroxy, amino, alkoxy, optionally substituted aryloxy, optionally substituted benzyloxy, alkylamino, dialkylamino, halo, trifluoromethyl, trifluoromethoxy, nitro, alkyl, carboxy, carbalkoxy, carbamoyl,
 10 alkylcarbamoyl, or R_5 and R_6 together represent methylenedioxy, carbonyldioxy or carbonyldiamino;
 X represents a hydroxy or an alkoxy group wherein the alkyl group may be substituted or unsubstituted or X represents a group NR_5R_t wherein R_5 and R_t each independently
 15 represent hydrogen, alkyl, substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted arylalkyl, an optionally substituted heterocyclic group or an optionally substituted heterocyclylalkyl group, or R_5 and R_t together with the nitrogen to which they are attached form a heterocyclic group; and
 Y represents O or S and Z represents CH, CH=CH or N; or
 20 Y represents NR_7 wherein R_7 represents hydrogen, hydroxy, alkanoyl, alkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, carbalkoxyalkyl, carbamoyl or aminosulphonyl and Z represents CH=CH or N.
2. A compound according to claim 1, wherein Y represents O or S and Z represents CH,
 25 CH=CH or N.
3. A compound according to claim 1 or claim 2, wherein Z represents CH or CH=CH
4. A compound according to any one of claims 1 to 3, wherein R_1 represents methyl.
5. A compound according to any one of claims 1 to 4, wherein R_2 , R_3 and R_4 each independently represent hydrogen.
- 30 6. A compound according to any one of claims 1 to 5, wherein X represents NR_5R_t , wherein R_t is hydrogen and R_5 represents a group of formula (H1):




(H1)

wherein X_1 , X_2 , X_3 , X_4 , X_5 , X_6 , X_7 and X_8 are each independently selected from hydrogen, hydroxy, (C_1-C_6) , alkyl cycloalkyl (spirocondensed), mono or poly hydroxyalkyl, alkoxyalkyl, hydroxy-alkoxyalkyl, alkanoyl, alkoxycarbonyl, aminoalkyl (optionally alkylated or acylated at nitrogen);

or one of X_4 with X_6 and X_2 with X_8 represents a C_{2-4} alkylene chain and the remaining variables X_1 , X_3 , X_7 and X_9 each independently represent hydrogen, hydroxy, lower alkyl (C_1-C_6) , cycloalkyl (spirocondensed), mono or poly hydroxyalkyl, alkoxyalkyl, hydroxy-alkoxyalkyl, alkanoyl, alkoxycarbonyl, aminoalkyl (optionally alkylated or acylated at nitrogen); and X_5 represents hydrogen or lower alkyl, mono or polyhydroxyalkyl, mono or diaminoalkyl, aminocarbonyl, alkyl, carboxyalkyl, carbalkoxyalkyl, aryl, heterocyclyl, acyl, carbamoyl, alkylamino(cyanimidoyl), aminoalkanoyl, hydroxyalkanoyl.


7. A process for the preparation of a compound of formula (I) or a salt thereof or a solvate thereof, which process comprises reacting a compound of formula (II):




(II)

wherein R_2 , R_3 , R_4 , R_5 , R_6 , Y and Z are as defined in relation to formula (I), with a

20 reagent capable of converting a moiety of formula



into a moiety of



(a)

wherein R₁, R₂, R₃, R₄ and X are as defined in relation to formula (I);

and thereafter, as necessary, carrying out one or more of the following reactions:

- (i) converting one compound of formula (I) into another compound of formula (I);
 - (ii) removing any protecting group;
 - 5 (iii) preparing a salt or a solvate of the compound so formed.
8. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a salt thereof or a solvate thereof, and a pharmaceutically acceptable carrier therefor.
9. A compound of formula (I) according to claim 1, or a pharmaceutically acceptable
10 salt thereof, or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.
10. A method for the treatment and/or prophylaxis of diseases associated with over activity of osteoclasts in mammals which method comprises the administration of an effective non-toxic amount of a compound of formula (I) according to claim 1, or a
15 pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/EP 97/03709

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D307/80 C07D333/60 C07D215/12 C07D405/06 C07D409/06
A61K31/47 A61K31/445 A61K31/34 A61K31/38

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 96 21644 A (SMITHKLINE BEECHAM SPA ; FARINA CARLO (IT); GAGLIARDI STEFANIA (IT)) 18 July 1996 cited in the application see abstract; claims 1, 14-20; examples ---	1-10
A	EP 0 449 196 A (TAKEDA CHEMICAL INDUSTRIES LTD) 2 October 1991 see page 39 - page 40; claim 1; table 2 ---	1-10
A	WO 92 14709 A (CAMBRIDGE NEUROSCIENCE INC) 3 September 1992 see abstract; claim 1 ---	1-10
A	EP 0 189 936 A (USV PHARMA CORP) 6 August 1986 see abstract; claim 1; examples 1-12 --- -/-	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

31 October 1997

Date of mailing of the international search report

13.11.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Paisdor, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 97/03709

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CHEMICAL ABSTRACTS, vol. 108, no. 25, 20 June 1988 Columbus, Ohio, US; abstract no. 217684j, D.P. POPA ET AL.: "Synthesis of abscisic acid analogs with antitranspirant properties" page 201; column 2; XP002045406 see abstract & IZV. AKAD. NAUK MOLD. SSR, SER. BIOL. KHIM. NAUK, no. 6, 1987, pages 54-56,</p> <p>-----</p>	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internati Application No

PCT/EP 97/03709

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9621644 A	18-07-96	IT MI950030 A	10-07-96
		AU 4536096 A	31-07-96
		EP 0802902 A	29-10-97
		NO 973178 A	09-09-97
EP 0449196 A	02-10-91	CA 2038925 A	27-09-91
		JP 4211651 A	03-08-92
		US 5296499 A	22-03-94
WO 9214709 A	03-09-92	US 5312928 A	17-05-94
		AU 1530692 A	15-09-92
EP 0189936 A	06-08-86	US 4758586 A	19-07-88
		AU 5296486 A	07-08-86
		DK 48886 A	02-08-86
		JP 61225145 A	06-10-86